These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1412 related items for PubMed ID: 34284148

  • 1. Outcomes with CD34-Selected Stem Cell Boost for Poor Graft Function after Allogeneic Hematopoietic Stem Cell Transplantation: A Systematic Review and Meta-Analysis.
    Shahzad M, Siddiqui RS, Anwar I, Chaudhary SG, Ali T, Naseem M, Ahmed TF, Ahmed Z, Khurana S, Ahmed N, Balusu R, Singh AK, Hematti P, Callander NS, Abhyankar SH, McGuirk JP, Mushtaq MU.
    Transplant Cell Ther; 2021 Oct; 27(10):877.e1-877.e8. PubMed ID: 34284148
    [Abstract] [Full Text] [Related]

  • 2. Durable Engraftment and Excellent Overall Survival After CD34-Selected Peripheral Blood Stem Cell Boost in Pediatric Patients With Poor Graft Function Following Allogeneic Stem Cell Transplantation.
    Fraint E, Farooki S, Klein E, Mauguen A, Prockop SE, Scaradavou A, Curran K, Cancio M, Spitzer B, Boelens JJ, Oved J, Harris A, O'Reilly RJ, Kernan NA.
    Transplant Cell Ther; 2023 Jan; 29(1):46.e1-46.e6. PubMed ID: 36210027
    [Abstract] [Full Text] [Related]

  • 3. Outcomes with mismatched unrelated donor allogeneic hematopoietic stem cell transplantation in adults: A systematic review and meta-analysis.
    Mushtaq MU, Shahzad M, Tariq E, Iqbal Q, Chaudhary SG, Zafar MU, Anwar I, Ahmed N, Bansal R, Singh AK, Abhyankar SH, Callander NS, Hematti P, McGuirk JP.
    Front Oncol; 2022 Jan; 12():1005042. PubMed ID: 36276084
    [Abstract] [Full Text] [Related]

  • 4. Poor graft function can be durably and safely improved by CD34+-selected stem cell boosts after allogeneic unrelated matched or mismatched hematopoietic cell transplantation.
    Haen SP, Schumm M, Faul C, Kanz L, Bethge WA, Vogel W.
    J Cancer Res Clin Oncol; 2015 Dec; 141(12):2241-51. PubMed ID: 26272482
    [Abstract] [Full Text] [Related]

  • 5. Fresh or Cryopreserved CD34+-Selected Mobilized Peripheral Blood Stem and Progenitor Cells for the Treatment of Poor Graft Function after Allogeneic Hematopoietic Cell Transplantation.
    Ghobadi A, Fiala MA, Ramsingh G, Gao F, Abboud CN, Stockerl-Goldstein K, Uy GL, Grossman BJ, Westervelt P, DiPersio JF.
    Biol Blood Marrow Transplant; 2017 Jul; 23(7):1072-1077. PubMed ID: 28323004
    [Abstract] [Full Text] [Related]

  • 6. Bone marrow versus peripheral blood allogeneic haematopoietic stem cell transplantation for haematological malignancies in adults.
    Holtick U, Albrecht M, Chemnitz JM, Theurich S, Skoetz N, Scheid C, von Bergwelt-Baildon M.
    Cochrane Database Syst Rev; 2014 Apr 20; 2014(4):CD010189. PubMed ID: 24748537
    [Abstract] [Full Text] [Related]

  • 7. Active infection at the time of CD34+ selected stem cell boost is associated with treatment failure and poor overall survival.
    Shapiro RM, Kim HT, Dulery R, Liney D, Garrity HM, Panaro K, Au C, Gervais C, Little JS, Ho VT, Cutler CS, Koreth J, Gooptu M, Antin JH, Kelkar AH, Romee R, Wu CJ, Ritz J, Soiffer RJ, Nikiforow S.
    Blood Adv; 2024 Sep 10; 8(17):4729-4737. PubMed ID: 38748871
    [Abstract] [Full Text] [Related]

  • 8. CD34(+)-selected stem cell boost without further conditioning for poor graft function after allogeneic stem cell transplantation in patients with hematological malignancies.
    Klyuchnikov E, El-Cheikh J, Sputtek A, Lioznov M, Calmels B, Furst S, Chabannon C, Crocchiolo R, Lemarié C, Faucher C, Bacher U, Alchalby H, Stübig T, Wolschke C, Ayuk F, Reckhaus ML, Blaise D, Kröger N.
    Biol Blood Marrow Transplant; 2014 Mar 10; 20(3):382-6. PubMed ID: 24321747
    [Abstract] [Full Text] [Related]

  • 9. CD34+ selected peripheral blood Stem Cell Boost (SCB) for Poor Graft Function (PGF) or mixed chimerism in pediatric patients, after hematopoietic stem cell transplantation: Results of a retrospective multicenter study.
    Berger M, Faraci M, Saglio F, Giardino S, Ernestina Vassallo E, Prete A, Fagioli F.
    Pediatr Transplant; 2021 Aug 10; 25(5):e13909. PubMed ID: 33141997
    [Abstract] [Full Text] [Related]

  • 10. Universal Engraftment after Allogeneic Hematopoietic Cell Transplantation Using Cryopreserved CD34-Selected Grafts.
    Jacob RP, Flynn J, Devlin SM, Maloy M, Giralt SA, Maslak P, O'Reilly RJ, Tonon JA, Perales MA, Avecilla ST, Cho C.
    Transplant Cell Ther; 2021 Aug 10; 27(8):697.e1-697.e5. PubMed ID: 33991721
    [Abstract] [Full Text] [Related]

  • 11. Impact of natural killer cells on outcomes after allogeneic hematopoietic stem cell transplantation: A systematic review and meta-analysis.
    Mushtaq MU, Shahzad M, Shah AY, Chaudhary SG, Zafar MU, Anwar I, Neupane K, Khalid A, Ahmed N, Bansal R, Balusu R, Singh AK, Abhyankar SH, Callander NS, Hematti P, McGuirk JP.
    Front Immunol; 2022 Aug 10; 13():1005031. PubMed ID: 36263054
    [Abstract] [Full Text] [Related]

  • 12. Boost of CD34+-selected peripheral blood cells without further conditioning in patients with poor graft function following allogeneic stem cell transplantation.
    Larocca A, Piaggio G, Podestà M, Pitto A, Bruno B, Di Grazia C, Gualandi F, Occhini D, Raiola AM, Dominietto A, Bregante S, Lamparelli T, Tedone E, Oneto R, Frassoni F, Van Lint MT, Pogliani E, Bacigalupo A.
    Haematologica; 2006 Jul 10; 91(7):935-40. PubMed ID: 16818281
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. CD3+TCRαβ/CD19+-Depleted Mismatched Family or Unrelated Donor Salvage Stem Cell Transplantation for Graft Dysfunction in Inborn Errors of Immunity.
    Ramanathan S, Lum SH, Nademi Z, Carruthers K, Watson H, Flood T, Owens S, Williams E, Hambleton S, Gennery AR, Slatter M.
    Transplant Cell Ther; 2023 Aug 10; 29(8):513.e1-513.e9. PubMed ID: 37279857
    [Abstract] [Full Text] [Related]

  • 15. CD34 Stem Cell Boost in Pediatric Allogeneic Stem Cell Transplant Recipients: A Case Series and Review of Literature.
    Bowman S, Stanek J, Bajwa R, Polishchuk V, Abu-Arja R, Rangarajan HG.
    Clin Hematol Int; 2023 Jun 10; 5(2-3):155-164. PubMed ID: 37027103
    [Abstract] [Full Text] [Related]

  • 16. Haploidentical Transplantation with Post-Transplant Cyclophosphamide versus Unrelated Donor Hematopoietic Stem Cell Transplantation: A Systematic Review and Meta-Analysis.
    Arcuri LJ, Aguiar MTM, Ribeiro AAF, Pacheco AGF.
    Biol Blood Marrow Transplant; 2019 Dec 10; 25(12):2422-2430. PubMed ID: 31386903
    [Abstract] [Full Text] [Related]

  • 17. Real-World Outcomes of Graft-versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation in Japan: Retrospective Analysis of the Transplant Registry Unified Management Program Registry.
    Kanda J, Mitsuyoshi T, Sakurai M, Nishimori H, Murata M, Uchida N, Doki N, Inamoto Y, Nishida T, Tanaka M, Katayama Y, Eto T, Matsuoka KI, Yoshihara S, Sawa M, Kawakita T, Jun G, Kurata M, Ichinohe T, Fukuda T, Teshima T, Atsuta Y, Terakura S.
    Transplant Cell Ther; 2024 Sep 10; 30(9):907.e1-907.e16. PubMed ID: 38960321
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Outcomes of allogeneic haematopoietic stem cell transplantation from HLA-matched and alternative donors: a European Society for Blood and Marrow Transplantation registry retrospective analysis.
    Shouval R, Fein JA, Labopin M, Kröger N, Duarte RF, Bader P, Chabannon C, Kuball J, Basak GW, Dufour C, Galimard JE, Polge E, Lankester A, Montoto S, Snowden JA, Styczynski J, Yakoub-Agha I, Mohty M, Nagler A.
    Lancet Haematol; 2019 Nov 10; 6(11):e573-e584. PubMed ID: 31477550
    [Abstract] [Full Text] [Related]

  • 20. Graft Failure Incidence, Risk Factors, and Outcomes in Patients Undergoing Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation Using Post-Transplant Cyclophosphamide.
    Mata JR, Zahurak M, Rosen N, DeZern AE, Jones RJ, Ambinder AJ.
    Transplant Cell Ther; 2024 Jun 10; 30(6):588-596. PubMed ID: 38521411
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 71.